Evidence map›Paper›PMID 34242744›Full record

GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2021

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

H J Burstein, G Curigliano, B Thürlimann, W P Weber, P Poortmans, M M Regan, H J Senn, E P Winer, M Gnant, Panelists of the St Gallen Consensus Conference

Open access · bronzeAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 450 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
450citing papers in PubMed, 7 pooled it
51.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

450 citing papers in PubMed, 7 syntheses or guidelines pooled it, 770 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Enhanced anticancer efficacy ofMaterials today. Bio · 2026
    Article
  18. Article
  19. Determinants of stage at breast cancer diagnosis across different healthcare systems: an international multicentre cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  20. Article

390 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 5 countries.

H J BursteinDana-Farber Cancer Institute, Harvard Medical School, Boston, USA. Electronic address: hburstein@partners.org.
G CuriglianoEuropean Institute of Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
B ThürlimannCantonal Hospital, St. Gallen, Switzerland.
W P WeberUniversity of Basel, Basel, Switzerland.
P PoortmansUniversity of Antwerp, Antwerp, Belgium.
M M ReganDana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
H J SennSt. Gallen Oncology Conferences (Foundation SONK), St. Gallen, Switzerland.
E P WinerDana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
M GnantMedical University of Vienna, Vienna, Austria.
Panelists of the St Gallen Consensus Conference
University of St.Gallen · CHBoston University · USHarvard University · USMedical University of Vienna · ATUniversity of Antwerp · BEUniversity of Basel · CHUniversity of Milan · ITConference Board · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-annual critical review of the 'state of the art' in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix 1) from all continents discussed and commented on the previously elaborated consensus questions, as well as many key questions on early breast cancer diagnosis and treatment asked by the audience. The theme of this year's conference was 'Customizing local and systemic therapies.' A well-organized program of pre-recorded symposia, live panel discussions and real-time panel voting results drew a worldwide audience of thousands, reflecting the far-reaching impact of breast cancer on every continent. The interactive technology platform allowed, for the first time, audience members to ask direct questions to panelists, and to weigh in with their own vote on several key panel questions. A hallmark of this meeting was to focus on customized recommendations for treatment of early-stage breast cancer. There is increasing recognition that the care of a breast cancer patient depends on highly individualized clinical features, including the stage at presentation, the biological subset of breast cancer, the genetic factors that may underlie breast cancer risk, the genomic signatures that inform treatment recommendations, the extent of response before surgery in patients who receive neoadjuvant therapy, and patient preferences. This customized approach to treatment requires integration of clinical care between patients and radiology, pathology, genetics, and surgical, medical and radiation oncology providers. It also requires a dynamic response from clinicians as they encounter accumulating clinical information at the time of diagnosis and then serially with each step in the treatment plan and follow-up, reflecting patient experiences and treatment response.

Indexed as

Breast NeoplasmsCOVID-19FemaleHumansNeoadjuvant TherapyPandemicsSARS-CoV-2adjuvantgenetic testingneoadjuvantradiation therapysurgerysurvivorship

Identifiers

PMID34242744
PMCPMC9906308
OpenAlexW3179495039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.